The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,358,179 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Revidia Therapeutics, Inc. The funding supports IND-enabling safety and toxicity testing of a novel subcutaneous formulation of the PTP1B inhibitor MSI-1436 as a treatment for fatal cardiomyopathy in Duchenne muscular dystrophy (DMD) patients. The studies will validate the subcutaneous dose formulation, perform repeat-dose toxicology and safety pharmacology testing, with the goal of enabling an IND application submission in early 2025 and initiation of clinical trials later that year. This work aims to develop a new therapeutic approach to address the leading cause of mortality in DMD, which currently lacks any approved medications.
Generated 3/4/25, 4:28 AM